EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor

Neurological Research

Volumn 31, Issue 3, 2009, Pages 313-315

  Okuyucu, Esra E ^a   Guven, Oguz ^a   Duman, Taskin ^a   Gorur, Sadik ^a   Melek, Ismet M ^a   Akcin, Soner ^a   Yilmazer, Serkan ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

Electroencephalography; Phosphodiesterase type 5 inhibitor; Tadalafil

Indexed keywords

TADALAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EEG ABNORMALITY; ELECTROENCEPHALOGRAM; ERECTILE DYSFUNCTION; HOSPITAL ADMISSION; HUMAN; MALE; RISK ASSESSMENT;

CARBOLINES; COHORT STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ELECTROENCEPHALOGRAPHY; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; TIME FACTORS;

EID: 65749096748     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X382548     Document Type: Article

References (18)

1. Berger H. Über das Elektrenkephalogram des Menschen. Arch Psychiatr Nervenkr 1929; 87: 527-570
2. Niedermeyer E, Dasilva F. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields, Baltimore: Williams & Wilkins, 1999
3. Wang X, Robinson PJ. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem 1997; 68: 443-456 (Pubitemid 27044703)
4. Loughney K, Hill TR, Florio VA, et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMPspecific 3',5'-cyclic nucleotide phosphodiesterase. Gene 1998; 216: 139-147
5. American Electroencephalographic Society. Guidelines in EEG and evoked potentials. J Clin Neurophysiol 1986; 3 (Suppl. 1): 1-152
6. Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 159: 109-115
7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
8. Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A, et al. Male erectile dysfunction and health-related quality of life. Eur Urol 2003; 44: 245-253
9. Gresser U, Gleiter CH. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadanafil - Review of the literature. Eur J Med Res 2002; 7: 435-446
10. Schultheiss D, Muller SV, Nager W, et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: A study with event-related brain potentials. World J Urol 2001; 19: 46-50
11. Kurt M, Bilge SS, Aksoz E, et al. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol J Pharmacol 2004; 56: 353-357
12. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathology and pharmacology. Pharmacol Rev 1991; 43: 109
13. Snyder SH, Bredt DS. Nitric oxide as a neural messenger. Trends Pharmacol Sci 1991; 12: 125-128
14. Pizegalinsky E, Baran L, Siwanowicz J. The role of nitric oxide in chemically- and electrically-induced seizures in mice. Neurosci Lett 1996; 2173: 145-148 (Pubitemid 26358823)
15. Striano P, Zara F, Minetti C, et al. Epileptic seizures can follow high doses of oral vardenafil. BMJ 2006; 333: 785
16. Kirkby RD, Carroll DM, Grossman AB, et al. Factors determining proconvulsant and anticonvulsant effect of inhibitors of nitric oxide synthase in rodents. Epilepsy Res 1996; 24: 91-100
17. Rajasekaran K, Jayakumar R, Kaliyamurthy V. Increased neuronal nitric oxide synthase (nNOS) activity triggers picrotoxin-induced seizure in rats and evidence for participation of nNOS mechanism in the action of antiepileptic drugs. Brain Res 2003; 979: 85-97 (Pubitemid 36792159)
18. Gilad R, Lampl Y, Eshel Y, et al. Tonic-clonic seizures in patients taking sildenafil. BMJ 2002; 325: 869